Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2018 Feb 7;8:2561. doi: 10.1038/s41598-018-20951-8

Generation and characterization of a IgG monoclonal antibody specific for GM3 (NeuGc) ganglioside by immunizing β3Gn-T5 knockout mice

Dongwei He 1,#, Xiaoyan Fan 2,✉,#, Boyi Liu 3,#, Yiqing Tian 2,4, Xiangmei Zhang 5, Lin Kang 6, Yan Tai 7, Shuzhen Liu 2, Qian Wang 2, Qingxia Li 2, Jianhui Cai 2
PMCID: PMC5803271  PMID: 29416099

Abstract

A murine monoclonal antibody (MAb-1) specific for GM3 has been generated by immunizing β3Gn-T5 knockout mice with purified GM3 ganglioside. The binding specificity of MAb-1 (IgG3 subclass) was established by an enzyme-linked immunosorbent assay (ELISA) and FACS and the antibody showed high binding specificity with GM3. Cell viability assay showed that MAb-1 significantly suppressed cell growth. Immunohistochemistry analysis revealed that MAb-1 was strongly expressed in human ovarian cancer tissues, whereas it was hardly expressed in normal tissues. Finally, antibody-dependent cellular cytotoxicity (ADCC) activities were determined by measuring lactate dehydrogenase (LDH) releasing assay and the results showed high ADCC activities in two representative ovarian cancer cell lines (OVHM and ID8). All of these data indicate that MAb-1 may be potentially used as a therapeutic antibody against ovarian cancers in clinical trials.

Introduction

Gangliosides, a kind of sialic acid-containing glycosphingolipids, are highly enriched in the central nervous system of vertebrates1,2. They are essentially located on the outlet of the cell membrane in various organs and tissues. Gangliosides are suggested to mediate a variety of cell functions, including cell-cell recognition, cell growth, cell adhesion, transmembrance signaling3–6, etc. Recently, growthing evidence have shown that the expression of gangliosides is increased in several pathological conditions, such as neurodegenerative disorders, immune diseases and tumors7–11. For example, many studies have established that gangliosides are targets of active specific immunotherapy in colon carcinoma, glioblastomas12,13, pancreatic adenocarcinoma and melanoma11. However, most of the monoclonal antibodies used in these studies showed relatively low binding affinity against gangliosides because they are of the IgM subclass14–16. Recently, we and other teams have established that gene-engineered mice may be useful for the generation of IgG antibodies due to their absence of some series of glycosphingolipids17–22.

The Lc3-synthase (β1,3-N-acetylglucosaminyltransferase-V:β3Gn-T5) is the key enzyme that controls the expression of lacto-/neolacto-series glycolipids by transferring GlcNAc in a β1,3-linkage to lactosylceramide (Fig. 1)23. The β3Gn-T5 is highly expressed during mouse development. It becomes mostly active on embryonic day 15, then decreases to a low level, and finally locates mainly in the spleen and placenta of adult mice23. Recently, we have established that β3Gn-T5 knockout mice showed about 2–8 times higher response when immunized with anti-glycolipid antigens compared with C57BL/6-background wild-type mice22. A similar result was obtained in another independent study16. All of these studies suggest that β3Gn-T5 mice may be suitable animals for the generation of ganglisosides specific-monoclonal antibodies.

Figure 1.

Figure 1

Open in a new tab

Synthetic pathway of lacto-/neolacto-series gangliosides. β3Gn-T5 synthesizes GlcNAc β1,3Galβ1,4Glc-ceramide to initiate the formation of lacto-/neolacto-series glycosphingolipids by transferring GlcNAc in a β1,3-linkage to lactosylceramide. Most glycosphingolipids were synthesized via Glc-Cer, while others were synthesized via Gal-Cer pathway. Cer, ceramide; Glc-Cer, glucosylceramide; Gal-Cer, galactosylceramide. In addition, β3Gn-T5 was shown red in the figure.

In the present study, we generated an anti-GM3 ganglioside monoclonal antibody (MAb-1) by immunizing β3Gn-T5 knockout mice with purified GM3 ganglioside. Furthermore, we determined the antibody specificity and reactivity. Our data indicated that MAb-1 may be a potential therapeutic antibody against human ovarian cancers in clinical trials.

Materials and Methods

Ethics statement

The experimental protocol was approved by Hebei General Hospital. The experimental methods and protocols were carried out in accordance with the approved guidelines and regulations. The animals used in this study were conducted under the guidelines for Animal Welfare and Experimentation of Hebei General Hospital.

Animals

β3Gn-T5 knockout mice were bred and maintained under special pathogen-free (SPF) conditions as described before22. C57BL/6J mice were purchased from Experimental Animal Center, Hebei Medical University. They were bred and maintained under the same conditions of β3Gn-T5 knockout mice.

Cell lines

Mouse ovarian cancer cell line OVHM was a gift from Dr. Hiromi Fujiwara (Osaka University, Osaka, Japan) and were cultured in RPMI1640 medium (Sigma-Aldrich, St. Louis, MO, USA) containing 10% fetal calf serum (Sijiqing Biological Engineering Materials CO., Ltd, Zhejiang, China) in our lab. Mouse ovarian cancer cell line ID8 was contributed by Professor Jianxin Cheng (Department of Gynecology, 4th hospital, Hebei Medical University, Shijiazhuang, China). ID8 cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma-Aldrich) supplemented with 4% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 5 µg/ml insulin, 5 µg/ml transferring and 5 ng/ml sodium selenite. Chinese hamster ovary (CHO) cells (Cell Bank of Type Culture Collection of Chinese Academy of Sciences, Shanghai, China) were cultured in RPMI1640 containing 10% fetal calf serum. The human epidermoid carcinoma cell line, A431 cell line (Cell Bank of Type Culture Collection of Chinese Academy of Sciences, Shanghai, China) was cultured in DMEM supplemented with 10% fetal bovine serum. All of the cells were maintained in a humidified atmosphere of 5% CO2 at 37 °C.

Drug preparations

Purified GM3 (NeuGc) ganglioside was isolated from horse erythrocytes as described previously24. GM3 (NeuAc), GM2, GM1, GD2, GD1b, GT1b were also purchased from Sigma-Aldrich (St.Louis, MO, USA). GD3 and Gb3 were gifts from Professor Zhongning Zhu (Basic Medical College, Hebei Medical University). GM2 (NeuGc) was obtained from liver of Balb/c mice as described before25. Sino Biological Mouse Mab Antibody isotyping kit was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).

Immunization of mice

8-week-old mice were immunized from the tail vein with liposomes (Sigma-Aldrich) containing GM3 ganglioside (100 μg) on day 1, 4, 8, 12, 16 and 20. The antibody titer in mouse serum was determined using ELISA assay. The details have been previously described17–22.

Enzyme-linked immunosorbent assay (ELISA)

Gangliosides (2 ng/μl) were plated in 96-well plates. After drying up in the air, 5% BSA was added for 2 h at room temperature. A series of diluted MAb-1 were added to the plates and incubated for another 2 h, followed by horseradish peroxidase (HRP)-anti-mouse IgG (Amersham Biosciences) as a secondary antibody. Finally, 10 μl of substrate solution [ortho-phenylene diamine (2 mg) (Sigma) and H2O2 (8 μl) (Sigma) in 5 ml of citrate-phosphate buffer] was added to stop the reaction. The optical density was recorded at 450 nm with a scanner. The isotype control of mouse IgG3 was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).

Flow cytometry

Cell surface expression of GM3 was determined by FACSCaliverTM (Becton Dickinson). Briefly, about 1 × 106 cells were incubated with MAb-1(10 μg/ml) or isotype control(10 μg/ml) for 60 min on ice and then stained with FITC-conjugated goat anti-mouse antibody (H + L) (Cappel, Durham, NC) for 45 min. Finally, the CELLQuestTM program (Becton Dickinson, New Jersey, USA) was used to determine the positive cells.

Measurements of affinity of MAb-1

The affinity of MAb-1 antibody against GM3 ganglioside was determined using BIAcore 3000 system (BIA core, Piscataway, NJ). Firstly, the MAb-1 antibody was immobilized on the surface of biosensor chips and coupled with N-ethyl-N′-(3-dimethylaminopropyl) carbodiimide/N-hydroxysuccinimide according to the instructions of the manufacturer. Then, 1% BSA was used as a control. The affinity rate constants (association rate constant, Ka; disassociation rate constant, Kd) were determined. Finally, the affinity of MAb-1 (K) were calculated as K = Ka/Kd.

Cell viability assays

The cell viabilities of MAb-1 on OVHM and ID8 cells were determined by MTS (3-(4, 5-dimethylthiazol-2-yl)-5-(3–carboxymethoxyphenyl)-2-(4- sulphophenyl)-2H-tetazolium) assay according to the manufacturer’s instructions (Promega, USA). Cells were seeded in triplicate in 24-well plates and incubated overnight. Then cells were treated with MAb-1 at doses of 10, 20 and 40 μg/ml, respectively. After 0, 24, 48 and 72 h incubation, MTS solution was added to each well and incubated for 3 h at 37 °C in a humidified incubator. Finally, the absorbance at 490 nm was measured.

Immunohistochemistry analysis by MAb-1

Immunohistochemistry analysis was performed as follows. Briefly, 20% sucrose-fixed human ovarian cancer tissues were cut into 10 μm sections. Then, they were incubated with MAb-1 (15 μg/ml) or isotype control (15 μg/ml) at 4 °C overnight. Next, they were incubated with biotin-conjugated secondary antibody for 30 min at room temperature and then incubated with streptavidin-horseradish peroxidase complex for 30 min. Finally, the sections were incubated with 3, 3′-diaminobenzidine for 10 min and counterstained with hematoxylin. The immunostained slides were evaluated by two independent observers under the microscope. Positive staining was detected as a brown color of the cells. Five high-power fields were randomly selected, and the percentage of positive cells in these fields was counted. Tumors without staining or with weak staining (positive cell rate <10%) were classified as negative while tumors with moderate (10%≤ positive cell rate <75%) to intense staining (positive cell rate ≥75%) were classified as positive.

Isolation of peripheral blood mononuclear cells (PBMCs)

PBMCs of mice were isolated as follows: Firstly, 5 ml peripheral blood was collected and diluted by addition of an equal volume of 1× PBS. Then the diluted blood was carefully loaded over an equal volume of lymphoprep reagent (Mouse Lymphoprep Reagent kit, Beijing Solarbio Science & Technology Co., Ltd) in a 50 ml centrifuge tube. After centrifugation at 800 g for 20 min at room temperature, the distant band at the blood/lymphoprep was carefully transferred into a new tube. The harvested fraction was washed twice and finally a pellet of cells was obtained.

ADCC assay

OVHM and ID8 cells were used as target cells and fresh PBMCs were used as effector cells. The ADCC was evaluated using a LDH release assay (Promega, Madison, USA) in 96-well plates, according to the manufacturer’s protocol. Briefly, cells were incubated at 37 °C for 20 h. Then, 100 ng/ml MAb-1 was added into each well. Next, the effector cells were added into the well with the E:T ratios of 200:1, 100:1, 50:1, 20:1, 10:1, 5:1 and 2:1, respectively. After 4 h co-incubation, LDH release in the supernatants was determined at 490 nm. The percentage of cellular cytotoxicity was calculated using CytoTox 96 Non-Radioactive Cytotoxicity AssayTM (Promega) according to the manufacturer’s instructions. Data were graphed and analyzed using GraphPad Prism5.0.

Statistical analysis

The results were reported as mean ± SD. Statistical significances were performed by one-way analysis of variance (ANOVA) followed by Tukey post hoc test between groups and multiple comparisons. A p value of less than 0.05 was evaluated as statistically significant.

Results

Generation of an anti-GM3-specific monoclonal antibody

After immunization of 3 mice with GM3 ganglioside embedded in liposome, the titers in each mouse were determined by ELISA and the mouse with the highest titer of anti-GM3 were chose for the following experiment. Spleen cells were fused with NS-1 myeloma cells. After hypoxanthine-aminopterin-thymidine (HAT) selection, a number of Mabs reactive with GM3 ganglioside were generated. Briefly, about 316 clones were available from 921 clones, and 89 definitely positive clones were identified by immuno-fluorescence (IF) assay. Furthermore, these clones were subcloned and checked by IF assay again. Finally, only 13 clones were found to be significantly positive with glycolipids (data unpublished). Among them, MAb-1 was firstly established and tested on tumor immunity against ovarian carcinoma. As shown in Fig. 2, MAb-1 reacted with GM3 in a dose-dependent manner in ELISA.

Figure 2.

Figure 2

Open in a new tab

MAb-1 reacts with GM3 in a dose-dependent manner in ELISA. GM3 ganglioside was immobilized in the plates and incubated with diluted MAb-1 concentrations. Mouse IgG3 purchased from Santa Cruz Biotechnology was used as isotype control. The data presented are means ± SD from at least three independent experiments.

Specificity of MAb-1 against GM3 at cellular level

Flow cytometry was used to determine the specificity of MAb-1 at cellular level (Fig. 3A). The purple portion indicates the negative control and the green portion indicates the positive expression of GM3 ganglioside. Both CHO and A431 cell lines, which endogenously express GM3 gangliosides, were recognized by MAb-1, indicating identical specificity of MAb-1 against GM3 at cellular level.

Figure 3.

Figure 3

Open in a new tab

Characters of Mab-1 antibody. (A) Specificity of MAb-1 against CHO cells (left panel) and A431 cells (right panel). The purple (left) and the green (right) lines in each panel represent the control and Mab-1 groups, respectively. (B) Epitope determination of Mab-1 by ELISA assay. Nine gangliosides were immobilized and followed incubation with purified MAb-1 antibody. (C) Subclass of MAb-1. The method was performed according to the guide of Sino Biological Mouse Mab Antibody isotyping kit.

To further analyze the epitope of MAb-1 antibody, the antibody was tested against other a-series (GM2, GM1), b-series gangliosides (GD3, GD2, GD1), globo-series(Gb3) as well as against GM3 (NeuAc). As shown in Fig. 3B, no cross-reaction with other gangliosides was found. Moreover, the association and dissociation rate constants (Ka = 6.08 × 104 (mol/l s)−1 and Kd = 3.17 × 10−4 s−1) were determined, respectively. The affinity of MAb-1 (K = Ka/Kd) was calculated as 1.92 × 108 (mol/l)−1. Similarly, the affinity of 14F7 against GM3 ganglioside was 1.79 × 108(mol/l)−1, indicating that it has similar affinity compared with MAb-1.

Subclass of MAb-1 antibody

Next, the subclass of MAb-1 antibody was established using Sino Biological Mouse Mab Antibody isotyping kit (Fig. 3C). The results clearly showed that the subclass of MAb-1 was IgG3.

Cell viabilities inhibitions induced by MAb-1

To investigate the role of MAb-1 in cell viabilities, 2 mouse ovarian cancer cell lines (OVHM and ID8) were firstly treated with MAb-1 to check the expression of GM3 ganglioside and the results were shown in Fig. 4A,B. 10, 20 and 40 μg/ml of MAb-1 were used to determine cell viabilities (Fig. 4C,D). Compared with control cells, 10 μg/ml MAb-1 barely showed any effect on OVHM cells at 24 h and 48 h, while it only showed a little effect at 72 h in OVHM cells (p < 0.01). At 20 and 40 μg/ml, MAb-1 significantly inhibited cell proliferation rates at 48 h and 72 h (p < 0.01). Furthermore, the inhibitory effects showed time- and dose-dependent manners.

Figure 4.

Figure 4

Open in a new tab

MAb-1 inhibited cell viabilities of OVHM and ID8. Expression of GM3 ganglioside in mouse ovarian OVHM (A) and ID8 (B) cells. Cell viabilities were inhibited by MAb-1 in OVHM (C) and ID8 (D) cells. All data represent mean ± SD from at least three independent experiments. *p < 0.05, **p < 0.01 compared with control groups, respectively.

Immunohistochemistry analysis by MAb-1 against ovarian tissues

Since GM3 ganglioside is known to be strongly expressed in human ovarian cancer cells, immunohistochemistry analysis was performed to detect the immunoreactivity of MAb-1 on human ovarian cancer tissues. In total, 56 human ovarian cancer samples were checked and 43 were positive. This result indicated the immunoreactivity was about 76.79%. Immunostaining by MAb-1 was negative in normal ovarian tissues (Fig. 5A), but showed strong staining in a cell-surface and cytoplasm pattern in ovarian cancer cells, such as serous adenocarcinoma (Fig. 5B), mucinous adenocarcinoma (Fig. 5C) and metastatic adenocarcinoma (Fig. 5D). These results suggested that MAb-1 specifically reacted with GM3 ganglioside in human ovarian cancer tissues.

Figure 5.

Figure 5

Open in a new tab

Immunohistochemistry analysis by MAb-1 against human ovarian tissues. Representative images are shown (100×). (A) Normal ovary, (B) serous adenocarcinoma, (C) mucinous adenocarcinoma, (D) metastatic adenocarcinoma.

ADCC by MAb-1

ADCC effects induced by MAb-1 were evaluated by determining the activity of cytosolic LDH released by treating OVHM and ID8 cells, respectively. As shown in Fig. 6, (1) the results of cell-mediated cytotoxicity (%) in these two cell lines all reached maximum at E:T ratio of 200:1; (2) At E:T ratio of 200:1, 100:1 and 50:1, the cytotoxicity (%) in OVHM and ID8 cells showed significantly higher levels compared with that of control groups (p < 0.01); (3) The cytotoxicity showed an E:T ratio-dependent manner when treated with 100 ng/ml MAb-1; (4) The control mouse IgG did not cause any significant cell lysis (less than 10%). These results indicated that MAb-1 could generate specific ADCC effects in mouse ovarian cancer cells.

Figure 6.

Figure 6

Open in a new tab

ADCC mediated by MAb-1 or control IgG in mouse ovarian cancer cell lines OVHM and ID8 assessed using LDH release assay. E:T ratio was 200:1, 100:1, 50:1, 20:1, 10:1, 5:1 and 2:1. (A) OVHM cell line. (B) ID8 cell line. All data represent mean ± SD, **p < 0.01 compared with control groups. Results are representative of three independent experiments.

Discussion

Since 1985, it has been well known that glycosphingolipids are ubiquitous membrane components of various organs2. Although they are natural components of the plasma membranes of vertebrates, numerous evidence indicate that gangliosides are attractive targets for immunotherapy due to different expression patterns during oncogenesis and tumor development26–30. Some of these gangliosides have been used as tumor markers or tumor-associated antigens in cancer diagnosis and therapy31–33. Especially, GM3 (NeuGc) is one of the most common types of sialic acid, which scarcely exists in normal human tissue but strongly expresses in glycoconjugates of human tumors34,35. These studies indicate that GM3 can be a potentially attractive target for cancer diagnosis and therapy. In view of the above points, a large number of antibodies, such as L61236, GMR615, 8G9D837, AbFCM138, have been established against NeuGc-containing gangliosides. At present, it is a little difficult for us to obtain these antibodies. However, we found that the subclass of L612, 8G9D8, GMR6 and AbFCMl was IgM, but not IgG subclass. In the application of reacting cancer cells with mAbs, IgG subclass mAbs are preferable, since they can be easily purified and possess immunological actions such as ADCC. Also, GMR6 exhibited broader specificities with GM4, GM1b, GD1a and GT1b. In addition to ganglioside GM3, 8G9D8 may bind to glycoproteins or another glycolipid of the stratum corneum in normal skin with a shared carbohydrate sequence. All of the above results have shown that MAb-1 monoclonal antibody in this study has valuable advantage in the future. Recently, 14F7, a IgG1 binding NeuGc-GM3 monoclonal antibody, was proved to bind specifically to GM3 (NeuGc) in breast, melanoma, colon and primary lymphoid tumors39–41. These results suggest that novel IgG antibodies specific to GM3 ganglioside can be reasonable and practicable.

In the present study, we used purified GM3 ganglioside to immunize β3Gn-T5 knockout mice to generate IgG monoclonal antibodies (IgG3 subclass) against human ovarian cancer tissues. β3Gn-T5 knockout mice, which lack Lc3-synthase, the key enzyme that controls the expression of lacto-/neolacto-series glycolipids, at some point, can enhance the antigen specificity. ELISA assay has shown that MAb-1 reacted with GM3 in a good dose-dependent manner. This result was also obtained by another independent study16. Furthermore, at cellular levels, the newly generated MAb-1 can significantly recognize cell lines that highly expressed GM3. These results further suggest that β3Gn-T5 knockout mice can be suitable animals for generating anti-glycolipid antigens with lacto-/neolacto-series structures.

It is generally accepted that NeuAc-gangliosides are expressed in normal tissues. Most studies have shown that NeuGc-gangliosides are widely expressed in human tumors39,42,43 and cell lines44. To our best knowledge, this is the first description of a murine IgG3 mAb specific for GM3 by immunizing β3Gn-T5 knockout mice. MAb-1 reacted with GM3 (NeuGc), but not GM3(NeuAc), suggesting that NeuGc structure affected MAb-1 binding. On the other hand, MAb-1 showed a little reactivity with GM2 ganglioside, indicating that the GalNAcβ1–4 residue significantly affect the binding efficacy of Mb-1. As for 14F7 antibody, similar results were found before27. Both of them showed specific reactivity with GM3 (NeuGc) ganglioside, suggesting that GM3(NeuGc) could be a suitable epitope.

It has been reported that most gangliosides (such as GM1, GD1a and GD3) of tumors, especially tumor microenvironment, can positively influence tumor growth10. As for GM3 ganglioside, early studies showed that exogenous GM3 inhibited the cell proliferation of several cancer cells43,45. However, the growth of the Siat9 (encoding GM3 synthase) and Galgt 1(encoding GM2 synthase)-deficient knockout tumor cells is significantly impeded both in vivo and in vitro10,46. The current data seem to suggest that the role of GM3 ganglioside in cell proliferation remains controversial. Here, in 2 ovarian cancer cell lines, MAb-1 treatment significantly inhibited the cell proliferation and showed good dose- and time- dependent manners. The discrepancies are likely due to the different concentrations of GM3 being used, different cell lines and tumor types and/or different administration of ganglioside-specific IgG antibodies.

It has been well established that ADCC is one of the immune effector mechanisms associated with antibodies against tumor-associated gangliosides47,48. The IgG Fc domain can interact with human FcγRs on effector cells and IgG3 is considered one of the principal human isotypes for activating FcγRs49. In the present study, the subclass of MAb-1 is IgG3 subclass and we further assessed the ability of MAb-1 to induce ADCC in ovarian cancer cells. Our results indicate that MAb-1 can induce remarkable ADCC effects on effector cells.

In conclusion, by immunizing β3Gn-T5 knockout mice with purified GM3 ganglioside, we successfully generated MAb-1 antibody. The MAb-1 reacted with GM3 in a dose-dependent manner in the ELISA assay. Furthermore, we detected the specific reaction of the antibody against ovarian cancer cells via immunohistochemistry and ADCC analysis. These results indicate that MAb-1 is a potentially effective IgG monoclonal antibody which may further be used in antibody-dependent diagnose and therapy of ovarian cancers.

Acknowledgements

The work was supported by National Natural Science Foundation of China (Grant No. 81301880 and 81603676), Natural Science Foundation of Hebei Province (Grant No. H2015206418), Major Research Project of Hebei Province (Grant No. zd2013006), projects from Health and Family Planning Commission of Hebei Province (Grant No. 20130251 and 20140160), Zhejiang Provincial Natural Science Funds for Distinguished Young Scholars (Grant No. LR17H270001) and Qianjiang Talent Program (Grant No.QJD1702020).

Author Contributions

D.H. and X.F. designed this paper, analyzed the results and prepared the manuscript. B.L., Y.T., X.Z. and Y.T. carried out the experiments, collected the data. L.K. and Q.W. prepared the immunohistochemistry experiment. S.L., Q.L. and J.C. participated in the manuscript discussion and helped the design.

Competing Interests

The authors declare no competing interests.

Footnotes

Dongwei He, Xiaoyan Fan and Boyi Liu contributed equally to this work.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Hakomori SI. Structure and function of glycosphingolipids and sphingolipids: recollections and future trends. Biochimica et biophysica acta. 2008;1780:325–346. doi: 10.1016/j.bbagen.2007.08.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature. 1985;314:53–57. doi: 10.1038/314053a0. [DOI] [PubMed] [Google Scholar]
  • 3.Kamimiya H, et al. Unique gangliosides synthesized in vitro by sialyltransferases from marine bacteria and their characterization: ganglioside synthesis by bacterial sialyltransferases. Journal of lipid research. 2013;54:571–580. doi: 10.1194/jlr.M026955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Julien S, Bobowski M, Steenackers A, Le Bourhis X, Delannoy P. How Do Gangliosides Regulate RTKs Signaling? Cells. 2013;2:751–767. doi: 10.3390/cells2040751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Hakomori S. Bifunctional role of glycosphingolipids. Modulators for transmembrane signaling and mediators for cellular interactions. The Journal of biological chemistry. 1990;265:18713–18716. [PubMed] [Google Scholar]
  • 6.Hakomori S, Igarashi Y. Functional role of glycosphingolipids in cell recognition and signaling. Journal of biochemistry. 1995;118:1091–1103. doi: 10.1093/oxfordjournals.jbchem.a124992. [DOI] [PubMed] [Google Scholar]
  • 7.Ariga T, McDonald MP, Yu RK. Role of ganglioside metabolism in the pathogenesis of Alzheimer’s disease–a review. Journal of lipid research. 2008;49:1157–1175. doi: 10.1194/jlr.R800007-JLR200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Hakomori S. Role of gangliosides in tumor progression. Progress in brain research. 1994;101:241–250. doi: 10.1016/S0079-6123(08)61953-6. [DOI] [PubMed] [Google Scholar]
  • 9.Piao H, et al. Affinity-matured recombinant immunotoxin targeting gangliosides 3’-isoLM1 and 3’,6’-isoLD1 on malignant gliomas. mAbs. 2013;5:748–762. doi: 10.4161/mabs.25860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Liu Y, Wondimu A, Yan S, Bobb D, Ladisch S. Tumor gangliosides accelerate murine tumor angiogenesis. Angiogenesis. 2014;17:563–571. doi: 10.1007/s10456-013-9403-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Morton DL, Ravindranath MH, Irie RF. Tumor gangliosides as targets for active specific immunotherapy of melanoma in man. Progress in brain research. 1994;101:251–275. doi: 10.1016/S0079-6123(08)61954-8. [DOI] [PubMed] [Google Scholar]
  • 12.Wikstrand CJ, et al. Occurrence of lacto series gangliosides 3’-isoLM1 and 3’,6’-isoLD1 in human gliomas in vitro and in vivo. Journal of neuropathology and experimental neurology. 1991;50:756–769. doi: 10.1097/00005072-199111000-00007. [DOI] [PubMed] [Google Scholar]
  • 13.Wikstrand CJ, et al. Lactotetraose series ganglioside 3’,6’-isoLD1 in tumors of central nervous and other systems in vitro and in vivo. Cancer research. 1993;53:120–126. [PubMed] [Google Scholar]
  • 14.Kawashima I, Nakamura O, Tai T. Antibody responses to ganglio-series gangliosides in different strains of inbred mice. Molecular immunology. 1992;29:625–632. doi: 10.1016/0161-5890(92)90199-8. [DOI] [PubMed] [Google Scholar]
  • 15.Kotani M, Ozawa H, Kawashima I, Ando S, Tai T. Generation of one set of monoclonal antibodies specific for a-pathway ganglio-series gangliosides. Biochimica et biophysica acta. 1992;1117:97–103. doi: 10.1016/0304-4165(92)90168-T. [DOI] [PubMed] [Google Scholar]
  • 16.Kato Y, et al. GMab-1, a high-affinity anti-3’-isoLM1/3’,6’-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice. Biochemical and biophysical research communications. 2010;391:750–755. doi: 10.1016/j.bbrc.2009.11.132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Takamiya K, et al. Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proceedings of the National Academy of Sciences of the United States of America. 1996;93:10662–10667. doi: 10.1073/pnas.93.20.10662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Okada M, et al. b-series Ganglioside deficiency exhibits no definite changes in the neurogenesis and the sensitivity to Fas-mediated apoptosis but impairs regeneration of the lesioned hypoglossal nerve. The Journal of biological chemistry. 2002;277:1633–1636. doi: 10.1074/jbc.C100395200. [DOI] [PubMed] [Google Scholar]
  • 19.Okuda T, et al. Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. The Journal of biological chemistry. 2006;281:10230–10235. doi: 10.1074/jbc.M600057200. [DOI] [PubMed] [Google Scholar]
  • 20.Kondo Y, et al. Glycosphingolipids are not pivotal receptors for Subtilase cytotoxin in vivo: sensitivity analysis with glycosylation-defective mutant mice. Biochemical and biophysical research communications. 2009;378:179–181. doi: 10.1016/j.bbrc.2008.10.163. [DOI] [PubMed] [Google Scholar]
  • 21.Liu Y, et al. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. The Journal of clinical investigation. 1999;103:497–505. doi: 10.1172/JCI5542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Fan X, et al. Strong antibody reaction against glycosphingolipids injected in liposome-embedded forms in beta3GN-T5 knockout mice. Nagoya journal of medical science. 2011;73:137–146. [PMC free article] [PubMed] [Google Scholar]
  • 23.Henion TR, Zhou D, Wolfer DP, Jungalwala FB, Hennet T. Cloning of a mouse beta 1,3 N-acetylglucosaminyltransferase GlcNAc(beta 1,3)Gal(beta 1,4)Glc-ceramide synthase gene encoding the key regulator of lacto-series glycolipid biosynthesis. The Journal of biological chemistry. 2001;276:30261–30269. doi: 10.1074/jbc.M102979200. [DOI] [PubMed] [Google Scholar]
  • 24.Fernandez-Marrero Y, Lopez-Requena A. Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions. mAbs. 2011;3:528–534. doi: 10.4161/mabs.3.6.17770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Suzuki A, Hashimoto Y, Abe M, Kiuchi Y, Yamakawa T. Genetic regulation of GM2 (NeuGc) expression in liver of mouse. Advances in experimental medicine and biology. 1984;174:263–272. doi: 10.1007/978-1-4684-1200-0_22. [DOI] [PubMed] [Google Scholar]
  • 26.Fredman P, Hedberg K, Brezicka T. Gangliosides as therapeutic targets for cancer. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2003;17:155–167. doi: 10.2165/00063030-200317030-00002. [DOI] [PubMed] [Google Scholar]
  • 27.Carr A, et al. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma. 2000;19:241–247. doi: 10.1089/02724570050109639. [DOI] [PubMed] [Google Scholar]
  • 28.Chu KU, et al. Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma. Cancer. 2000;88:1828–1836. doi: 10.1002/(SICI)1097-0142(20000415)88:8&#x0003c;1828::AID-CNCR11&#x0003e;3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  • 29.Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS letters. 2014;588:288–297. doi: 10.1016/j.febslet.2013.11.030. [DOI] [PubMed] [Google Scholar]
  • 30.Horwacik I, Rokita H. Targeting of tumor-associated gangliosides with antibodies affects signaling pathways and leads to cell death including apoptosis. Apoptosis: an international journal on programmed cell death. 2015;20:679–688. doi: 10.1007/s10495-015-1103-7. [DOI] [PubMed] [Google Scholar]
  • 31.Hakomori S. Possible functions of tumor-associated carbohydrate antigens. Current opinion in immunology. 1991;3:646–653. doi: 10.1016/0952-7915(91)90091-E. [DOI] [PubMed] [Google Scholar]
  • 32.Houghton AN, et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proceedings of the National Academy of Sciences of the United States of America. 1985;82:1242–1246. doi: 10.1073/pnas.82.4.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Zhang S, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. International journal of cancer. 1997;73:42–49. doi: 10.1002/(SICI)1097-0215(19970926)73:1&#x0003c;42::AID-IJC8&#x0003e;3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  • 34.Marquina G, et al. Gangliosides expressed in human breast cancer. Cancer research. 1996;56:5165–5171. [PubMed] [Google Scholar]
  • 35.Kawai T, Kato A, Higashi H, Kato S, Naiki M. Quantitative determination of N-glycolylneuraminic acid expression in human cancerous tissues and avian lymphoma cell lines as a tumor-associated sialic acid by gas chromatography-mass spectrometry. Cancer research. 1991;51:1242–1246. [PubMed] [Google Scholar]
  • 36.Hoon DS, et al. Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers. Cancer research. 1993;53:5244–5250. [PubMed] [Google Scholar]
  • 37.Paller AS, Siegel JN, Spalding DE, Bremer EG. Absence of a stratum corneum antigen in disorders of epidermal cell proliferation: detection with an anti-ganglioside GM3 antibody. The Journal of investigative dermatology. 1989;92:240–246. doi: 10.1111/1523-1747.ep12276782. [DOI] [PubMed] [Google Scholar]
  • 38.Furukawa K, Yamaguchi H, Oettgen HF, Old LJ, Lloyd KO. Two human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with corresponding mouse monoclonal antibodies. Cancer research. 1989;49:191–196. [PubMed] [Google Scholar]
  • 39.Lahera T, et al. Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer. Journal of oncology. 2014;2014:482301. doi: 10.1155/2014/482301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Blanco R, et al. Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Primary Lymphoid Tumors and Lymph Node Metastasis. Pathology research international. 2013;2013:920972. doi: 10.1155/2013/920972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Carr A, Mesa C, del Carmen Arango M, Vazquez AM, Fernandez LE. In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody. Hybridoma and hybridomics. 2002;21:463–468. doi: 10.1089/153685902321043990. [DOI] [PubMed] [Google Scholar]
  • 42.Torbidoni AV, et al. Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 Ganglioside in retinoblastoma tumours. Acta ophthalmologica. 2015;93:e294–300. doi: 10.1111/aos.12578. [DOI] [PubMed] [Google Scholar]
  • 43.Wang H, et al. Antitumor effects of exogenous ganglioside GM3 on bladder cancer in an orthotopic cancer model. Urology. 2013;81:210. doi: 10.1016/j.urology.2012.08.015. [DOI] [PubMed] [Google Scholar]
  • 44.Higashi H, Sasabe T, Fukui Y, Maru M, Kato S. Detection of gangliosides as N-glycolylneuraminic acid-specific tumor-associated Hanganutziu-Deicher antigen in human retinoblastoma cells. Japanese journal of cancer research: Gann. 1988;79:952–956. doi: 10.1111/j.1349-7006.1988.tb00060.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Bremer EG, Schlessinger J, Hakomori S. Ganglioside-mediated modulation of cell growth. Specific effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor. The Journal of biological chemistry. 1986;261:2434–2440. [PubMed] [Google Scholar]
  • 46.Liu Y, et al. Ganglioside synthase knockout in oncogene-transformed fibroblasts depletes gangliosides and impairs tumor growth. Oncogene. 2010;29:3297–3306. doi: 10.1038/onc.2010.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Chapman PB, Lonberg M, Houghton AN. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity. Cancer research. 1990;50:1503–1509. [PubMed] [Google Scholar]
  • 48.Dorvignit D, et al. Antitumor and cytotoxic properties of a humanized antibody specific for the GM3(Neu5Gc) ganglioside. Immunobiology. 2015;220:1343–1350. doi: 10.1016/j.imbio.2015.07.008. [DOI] [PubMed] [Google Scholar]
  • 49.Overdijk MB, et al. Crosstalk between human IgG isotypes and murine effector cells. J Immunol. 2012;189:3430–3438. doi: 10.4049/jimmunol.1200356. [DOI] [PubMed] [Google Scholar]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES